Targeting SUMO signaling to wrestle cancer

Kroonen, J.S.; Vertegaal, A.C.O. (2021)

Article / Letter to editor

The small ubiquitin-like modifier (SUMO) signaling cascade is critical for gene expression, genome integrity, and cell cycle progression. In this review, we discuss the important role SUMO may play in cancer and how to target SUMO signaling. Recently developed small molecule inhibitors enable therapeutic targeting of the SUMOylation pathway. Blocking SUMOylation not only leads to reduced cancer cell proliferation but also to an increased antitumor immune response by stimulating interferon (IFN) signaling, indicating that SUMOylation inhibitors have a dual mode of action that can be employed in the fight against cancer. The search for tumor types that can be treated with SUMOylation inhibitors is ongoing. Employing SUMO conjugation inhibitory drugs in the years to come has potential as a new therapeutic strategy.

• All authors: Kroonen, J.S.; Vertegaal, A.C.O.
• Date: 2021-06-01
• Journal: TRENDS IN CANCER
• Volume: 7
• Issue: 6
• Pages: 496 - 510
• DOI: doi:10.1016/j.trecan.2020.11.009
• Link: http://www.cell.com/article/S2405803320303101/pdf